A Urokinase Receptor-Bim Signaling Axis Emerges During EGFR Inhibitor Resistance in Mutant EGFR Glioblastoma

EGFR is the most common genetically altered oncogene in glioblastoma (GBM), but small molecule EGFR tyrosine kinase inhibitors (TKIs) have failed to yield durable clinical benefit. Here we show that in two novel model systems of acquired resistance to EGFR TKIs, elevated expression of urokinase plas...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Res
Autori principali: Wykosky, Jill, Hu, Jingjing, Gomez, German G., Taylor, Tiffany, Villa, Genaro R., Pizzo, Donald, VandenBerg, Scott R., Thorne, Amy Haseley, Chen, Clark C., Mischel, Paul S., Gonias, Steven. L., Cavenee, Webster K., Furnari, Frank B.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297573/
https://ncbi.nlm.nih.gov/pubmed/25432173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-2004
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi